Munir Ghesani

PET & SPECT imaging have long helped identify promising radiopharmaceutical targets. Advances in multi-omics, computational biology and quantitative imaging are providing richer insight into target expression, heterogeneity and in vivo behavior over time.

This workshop will explore how these approaches can be combined to distinguish interesting biological targets, and those that simply image well, from those most likely to translate into effective therapeutics.

• Identifying & prioritizing higher-potential targets: Integrating multi-omics and computational biology to assess tumor-to-healthy expression, prevalence, heterogeneity and therapeutic potential before progressing a target
• Looking beyond high tumor uptake: Determining whether a target that looks promising on an initial scan has the biological characteristics required for effective radiopharmaceutical therapy
• Understanding target behavior over time: Using longitudinal PET & SPECT to assess target engagement, retention, washout, clearance and tumor vs healthy-tissue biodistribution
• Building higher-confidence target go/no-go decisions: Combining computational, biological, and human imaging evidence to distinguish targets that simply look promising from those most likely to translate into effective therapeutics